Physician profile
William Stanley Rule
NPI 1164489167
$459.03
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $89.05 · 2021: $207.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $119.60 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $78.73 | 2021 | |
| Tris Pharma INC | $55.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.86 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $30.03 | 2019 | |
| Pfizer INC. | $29.22 | 2019-2020 | |
| Neos Therapeutics, LP | $16.76 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.38 | 2021 | |
| Neurelis, INC. | $13.54 | 2020 | |
| Aytu Biopharma, INC. | $13.53 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.